| Period of recruitment | Number of patients | Median number of biopsy cores | Median follow-up | Outcome |
---|---|---|---|---|---|
Grann et al., 1998 [16] | 1988–1994 | 103 | NA | 3 years | 5-year bPFS = LT < 10 mm: 74% LT > 10 mm: 36% (p = 0.011, univariate / p = 0.15 multivariate) |
Merrick et al., 2002 [57] | 1995–1999 | 262 (111 with exclusive brachytherapy) | 6 (2–15) | 38.6 months | 5-year bPFS = 92.5% PPB < 34%: 96.6% PPB 34–50%: 92.9% PPB > 50%: 84.8% (p = 0.017) PPB not associated with bPFS within each risk group. |
Merrick et al., 2004 [58] | 1995–2001 | 413 (197 with exclusive brachytherapy) | NA | 52 months | 7-year bPFS = PPB < 34%: 99.4% PPB 34–50%: 94.3% PPB > 50%: 89.2% (p = 0.002) |
Rossi et al., 2006 [17] | 1997–1999 | 108 | 12 | 61 months | 5-year bPFS = 87% PPB < 50%: 95% PPB > 50%: 63% (p < 0.0001) |
Guzzo et al., 2008 [18] | 1992–2002 | 245 | 6.8 (1–18) | 52.8 months | 5-year bPFS: 82% PPB < 27%: 89.1% PPB > 27%: 73.8% (p = 0.011) |
Merrick et al., 2008 [59] | 1995–2004 | 145 |  | 5.8 years | 9-year bPFS = 97.1% PPB = predictor of bPFS in multivariate analysis. |
Potters et al., 2008 [19] | 1992–2000 | 1449 | NA | 82 months | 12-year bPFS = 78% PPB independently associated with bPFS in the multivariate analysis (p = 0.037). |
Taira et al., 2011 [20] | 1995–2006 | 1656 (831 with exclusive brachytherapy) | NA | 7 years | 12-year bPFS = 95.6% PPB > 34%: 98% PPB 34–50%: 93% PPB > 50%: 91.5% (p < 0.001) |
Hill et al., 2015 [60] | 1998–2012 | 846 | 12 | 5.59 years | Biochemical failures: 62 (7.3%) Failures: PPB = 32.8% Non failures: PPB = 34.9% NS |
Martell et al., 2017 [61] | 2003–2013 | 2608 | NA | 4,7 years | Estimated 7-year-bPFS = 93% PPB not associated with bPFS. |
Present study | 2006–2013 | 282 | 12 (5–32) | 61 months | Biochemical failures: 20 (7.1%) Failures: PPB =17% Non failures: PPB = 17% NS |